glp-1 and fasting meal-stimulated time courses of and PYY in the two GLP-1 RAs for Fasting Patients:

Semaglutides patents are expiring in these countries from 2026 onwards, covering nations that together represent 40% of the worlds population and around 33% of adults living with obesity globally

Unexpected GLP-1 benefits among American women by generation: 47% of millennials feel an improvement in mood or reduced anxiety with GLP-1s, compared to 24% of baby boomers and 20% of Gen Z

in 1984 of leptin (45), a peripheral active appetite inhibiting hormone produced by adipocytes and acting both via specific receptor (Ob-R) on afferent vagal nerves and directly on ARC neurons enhancing satiety, raised a hope in progress in obesity therapy (44)

And so perhaps these drugs may be an early intervention, especially when we consider coupling it with hormone therapy to be able to prevent dementia